ArticleJournal of medical virology2008
Development of a TaqMan assay for the six major genotypes of hepatitis C virus: comparison with commercial assays.
Article in Journal of medical virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.Gastroenterology · 2010Pooled it
- Transfusion-associated hepatitis before the screening of blood for hepatitis risk factors.Transfusion · 2014Trial
- Article
- Article
- A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture.Microbiology spectrum · 2021Article
- Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography.PloS one · 2019Article
- Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.Science translational medicine · 2018Article
- Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.PLoS pathogens · 2018Article
- Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.Antiviral research · 2017Article
- A Single-step Multiplex Quantitative Real Time Polymerase Chain Reaction Assay for Hepatitis C Virus Genotypes.Journal of translational internal medicine · 2017Article
- Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge.Journal of virology · 2015Article
- Hepatitis B virus and hepatitis C virus infections in United States-bound refugees from Asia and Africa.The American journal of tropical medicine and hygiene · 2014Article
- Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles.Journal of virology · 2013Article
- Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection.PloS one · 2011Article
- Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences.Journal of virology · 2010Article
- Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.Journal of virology · 2010Article
- Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.The Journal of infectious diseases · 2010Article
- Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
A quantitative real-time PCR assay was developed that detects genomic RNA from reference strains representing the six major genotypes of hepatitis C virus (HCV) with equal sensitivity and accurately measured HCV RNA in JFH1 HCV-infected Huh7.5 cells. The method is indirectly calibrated to the first international (WHO 96/790) HCV standard preparation and has a linear dynamic range of 10(2.6)-10(6.5) IU/ml. In addition, the inter- and intra-assay precision were approximately 3% CV and <2% CV, respectively. Comparison with results obtained by commercially available HCV RNA Nucleic Acid Technology kits (Versant HCV RNA 3.0 b-DNA and Amplicor HCV Monitor), that also employ the WHO standard, allowed validation of the TaqMan assay against all major HCV genotypes. Both commercial methods detected HCV RNA over a wide dynamic range, but showed a consistent difference of about 0.3 log10 when evaluating samples of different HCV genotypes. The genome titers obtained with the three methods correlated with the infectivity titers previously determined for the HCV reference strains. TaqMan assays have become an essential tool to follow viral load in clinical samples and cell culture-based experiments and this technology offers significant advantages in linear dynamic range, sensitivity and customization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.